Menu Search
Equities

Jiangsu Recbio Technology Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
G93:FRA

Jiangsu Recbio Technology Co Ltd

Actions
  • Price (EUR)0.474
  • Today's Change0.018 / 3.95%
  • Shares traded12.87k
  • 1 Year change-56.51%
  • Beta0.0107
Data delayed at least 15 minutes, as of Feb 16 2026 14:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Jiangsu Recbio Technology Co Ltd is a China-based company engaged in vaccine research and development. The Company is still in the research and development stage. The Company's vaccine pipeline includes recombinant human papillomavirus (HPV) 9-valent vaccine, novel adjuvanted recombinant HPV 9-valent vaccine, recombinant HPV bivalent (Types 16/18) vaccine, recombinant HPV bivalent (Types 6/11) vaccine, novel adjuvanted recombinant HPV quadrivalent vaccine, novel adjuvanted recombinant shingles vaccine, novel adjuvanted recombinant respiratory syncytial virus vaccine, recombinant metapneumovirus vaccine, recombinant human cytomegalovirus vaccine, recombinant bicomponent COVID-19 vaccine, recombinant hepatitis B virus vaccine, and others.

  • Revenue in HKD (TTM)12.34m
  • Net income in HKD-740.61m
  • Incorporated2012
  • Employees507.00
  • Location
    Jiangsu Recbio Technology Co LtdNo. 888 Yaocheng AvenueChina Medical CityTAIZHOU ChinaCHN
  • Phone+86 52 386818860
  • Fax+86 52 386866018
  • Websitehttps://www.recbio.cn/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.